Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 202Carcinoma, Renal Cell 68Liver Neoplasms 61Neoplasms 53Neoplasm Metastasis 34Leukemia, Myeloid, Acute 34Carcinoma, Non-Small-Cell Lung 32Breast Neoplasms 29Melanoma 24Kidney Neoplasms 21Pancreatic Neoplasms 16Brain Neoplasms 15Sarcoma 14Prostatic Neoplasms 14Lung Neoplasms 14Recurrence 13Glioblastoma 13Thyroid Neoplasms 11Colorectal Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Carcinoma 10Urinary Bladder Neoplasms 8Rectal Neoplasms 8Ovarian Neoplasms 8Myelodysplastic Syndromes 8Multiple Myeloma 8Gliosarcoma 8Stomach Neoplasms 7Colonic Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6

Interventions

Everolimus 5Octreotide 4Leucovorin 4Temozolomide 3Oxaliplatin 3Fluorouracil 3Capecitabine 3vatalanib 2temsirolimus 2Trastuzumab 2Sirolimus 2Melphalan 2Irinotecan 2Biological Therapy 2Bevacizumab 2tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1napabucasin 1motesanib diphosphate 1irinotecan sucrosofate 1folfirinox 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1Vinorelbine 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Islet Cell × Sorafenib × Clear all
NCT00131911 2014-11-17

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
93 enrolled 10 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡